A review on telmisartan: A novel, long-acting angiotensin II-receptor antagonist

Cardiovascular Drug Reviews

Volumn 18, Issue 2, 2000, Pages 127-154

  Wienen, Wolfgang ^a   Entzeroth, Michael ^a,c   Van Meel, Jacobus C A ^a,d   Stangier, Joachim ^a   Busch, Ulrich ^a   Ebner, Thomas ^a   Schmid, Jochen ^a   Lehmann, Horst ^a   Matzek, Kandace ^a   Kempthorne Rawson, Joan ^b   Gladigau, Volker ^a   Hauel, Norbert H ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c CEREP   (France)

^d BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

ABPM; Angiotensin II (AT1) receptor antagonist; Hypertension; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; TELMISARTAN;

ANTIHYPERTENSIVE ACTIVITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HEART PROTECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033873784     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2000.tb00039.x     Document Type: Review

References (67)

1. Chronic toxicity evaluation of the nonsulfhydryl angiotensin converting enzyme inhibitor quinapril
2. Teratogen update: Angiotensin-converting enzyme inhibitors
3. Angiotensin II receptor blockade in TGR(mREN2)27: Effects of renin-angiotensin-system gene expression and cardiovascular functions
4. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade
5. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: Molecular mechanisms and pathology
6. The new angiotensin II receptor antagonist, irbesartan - Pharmacokinetic and pharmacodynamic considerations
7. Reproductive toxicity studies of rentiapril
8. Juxtaglomerular cell changes in normotensive rats treated with quinapril, an inhibitor of angiotensin converting enzyme
9. Acute, subchronic and chronic toxicity studies of the new angiotensin converting enzyme inhibitor ramipril
10. Fertility and perinatal/postnatal studies with the angiotensin-converting enzyme inhibitor, quinapril
11. Disposition and chemical stability of telmisartan 1-O-acylglucuronide
12. Angiotensin I1 receptors in the rat lung are of the AII-1 subtype
13. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
14. Angiotensin receptors and their antagonists
15. Effect of an angiotensin converting enzyme inhibitor on blood pressure and erythropoiesis in rats
16. Twelve month studies on the chronic toxicity of captopril in rats
17. Effect of angiotensin II and telmisartan, an angiotensin I receptor antagonist, on rat gastric mucosal blood flow
18. Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding
19. Histopathological and ultrastructural changes in the juxtaglomerular apparatus of the rat following administration of ZENECA ZD6888 (2-ethyl-5,6,7,8-tetrahydro-4-[(2'-(1H-tetrazol-5-yl)biphenyl-4-y l)-methoxy]quinoline), an angiotensin II antagonist
20. 1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension
21. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine
22. Renin and erythropoietin
23. 14C-candesartan cilexetil in healthy volunteers
24. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP 3174 in humans
25. Renal structure and function in rats given suprapharmacologic doses of quinapril, an angiotensin converting enzyme inhibitor
26. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild to moderate hypertension
27. Mechanisms of angiotensin action on vascular smooth muscle, the adrenal, and the kidney
28. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases
29. Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically-instrumented transgenic rats
30. Eprosartan
31. Maternotoxicity and fetotoxicity of an angiotensin-converting enzyme inhibitor, enalapril, in rabbits
32. Acute and 4-week subacute oral toxicity studies of lisinopril (MK-0521) in beagle dogs
33. Angiotensin-converting enzyme and the cough reflex
34. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene
35. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension
36. The morphology of juxtaglomerular cell hyperplasia and hypertrophy in normotensive rats and monkeys given an angiotensin II receptor antagonist
37. Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries
38. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor-antagonists: Synthesis, biological activity, and structure-activity relationships
39. The Renin Angiotensin System
40. Pharmacology of nonpeptide angiotensin II receptor antagonists
41. Once-daily telmisartan compared with enalapril in the treatment of hypertension
42. 1-selective angiotensin II receptor antagonist losartan in rats
43. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: Absolute bioavailability and effect of food
44. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart
45. Dilator effect of the angiotensin II antagonist telmisartan on the gastric, but not femoral, arterial bed of the rat
46. 1 receptor blockade on blood pressure and the renin angiotensin system in spontaneously hypertensive rats of the stroke prone strain
47. Extracellular matrix remodelling in heart failure. A role for de novo angiotensin II generation
48. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies
49. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
50. Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR 277 in the rat
51. 1) receptor antagonist, in conscious monkeys
52. I. Nonpeptide angiotensin II receptor antagonists: Insurmountable angiotensin II antagonism of EXP 3892 is reversed by the surmountable antagonist DuP 753